Compare NICE Ltd (NICE) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Twist Bioscience Corp — how do they compare? NICE Ltd trades at $117.58 (market cap $6.81B), while Twist Bioscience Corp trades at $161.11 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NICE Ltd for 15 Days and Twist Bioscience Corp for 27 Days on average.
| NICE | TWST | |
|---|---|---|
Market Cap | $6.81B | $10.08B |
Volume | 382,395 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $137.68 | $205.00 |
52-Week Low | $83.15 | $25.45 |
Typical Hold Time | 15 Days | 27 Days |
Enterprise Value | $6.54B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE trades at $117.76, up 1.15% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.70 exceeding expectations. Recent news highlights leadership in AI-driven contact center platforms and workplace innovation awards, supporting positive sentiment.
The outlook for NICE is positive, driven by AI revenue growth and solid fundamentals, but risks include margin compression from heavy AI investments and competitive pressures. With no sell ratings from analysts and institutional buying activity, the stock presents a favorable risk-reward profile for growth-oriented investors.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
